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High cholesterol deteriorates 
bone health: new insights into 
molecular mechanisms
Chandi C. Mandal*
Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Rajasthan, India
Many epidemiological studies show a positive connection between cardiovascular 
diseases and risk of osteoporosis, suggesting a role of hyperlipidemia and/or hypercho-
lesterolemia in regulating osteoporosis. The majority of the studies indicated a correlation 
between high cholesterol and high LDL-cholesterol level with low bone mineral density, 
a strong predictor of osteoporosis. Similarly, bone metastasis is a serious complication 
of cancer for patients. Several epidemiological and basic studies have established that 
high cholesterol is associated with increased cancer risk. Moreover, osteoporotic bone 
environment predisposes the cancer cells for metastatic growth in the bone microenvi-
ronment. This review focuses on how cholesterol and cholesterol-lowering drugs (statins) 
regulate the functions of bone residential osteoblast and osteoclast cells to augment or 
to prevent bone deterioration. Moreover, this study provides an insight into molecular 
mechanisms of cholesterol-mediated bone deterioration. It also proposes a potential 
mechanism by which cellular cholesterol boosts cancer-induced bone metastasis.
Keywords: osteoporosis, bone mineral density, bone remodeling, bone metastasis, osteoblast, osteoclast, 
cholesterol, statins
iNTRODUCTiON
As the life expectancy increases, the risk of developing various diseases, such as cardiovascular dis-
eases (CVD), osteoporosis, and cancer, increases with aging. Osteoporosis is a major health concern, 
especially for menopausal women, and it accounts for a significant economic burden worldwide. 
Epidemiological studies have linked an association of CVD with reduced bone mineral density 
(BMD) and with increased bone fracture (1–3). Low BMD is a strong predictor for osteoporosis-
associated fracture risk.
Many, but not all, studies have suggested a positive link between dyslipidemia [such as high 
serum total cholesterol (TC) and high low-density lipoprotein cholesterol (LDL-C)] and low BMD, 
especially for postmenopausal women (4–8). Moreover, a reduction of BMD was reported, when 
rodents were kept on high fat diet (9). Various clinical and animal studies have evidenced that 
cholesterol-lowering statin drugs, reduce osteoporosis-associated fracture risk (10–12). Similarly, a 
relationship between cancer risk and hypercholesterolemia was found from many epidemiological 
and basic studies (13–17). In our studies, we have demonstrated the active role of statins in osteoblast 
differentiation, which supports bone formation, but inhibited osteolytic metastasis of breast cancer 
(18, 19).
In this review, we have attempted to address the effect of cholesterol and statins on the activities 
of osteoblast and osteoclast cells, and overall bone health. This report also highlights the underlying 
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molecular mechanisms of high cholesterol-mediated bone 
deterioration.
iNvOLveMeNT OF vARiOUS CeLL TYPeS 
iN BONe ReMODeLiNG
Bone is an active and highly dynamic tissue, which is continu-
ously remodeled by a balanced and coordinated action of bone-
forming osteoblast and bone-resorbing osteoclast cells. In the 
osteoporotic condition, the rate of bone resorption exceeds that 
of bone formation either due to enhancement of osteoclast activ-
ity or impairment of osteoblast differentiation. Bone residential 
osteoblast, osteoclast, and osteocyte cells primarily regulate this 
physiological process. Mature osteoblast cells release several bone 
matrix proteins, such as collagen 1, osteocalcin (OCN), bone 
sialo protein (BSP), and osteopontin (OPN), to the extracellular 
environment. These components form osteoid (soft bone) (20). 
Osteoblasts also facilitate the formation of hydroxyapatite (HA; 
CaPO4) crystal inside the matrix vesicles (MVs). These MVs 
move to the extracellular environment, and unload the crystal 
molecules on the top of osteoid, which provides the cementing 
material, to make the matrix hard (21). In contrast to osteoblasts, 
multinucleated giant osteoclast cells release H+ ion to dissolve 
this cementing material, and secrete various proteolytic enzymes, 
such as tartrate resistant acid phosphatase (TRAP), collagenolytic 
cathepsin K, and matrix metalloproteinases (MMPs), to break 
down the bone matrix.
Osteoblasts/osteoblast lineage cells also produce osteoclasto-
genic factors, such as colony stimulating factor-1 (CSF-1), recep-
tor activator of NFκB ligand (RANKL), and osteoprotegerin OPG 
(20). These CSF-1 and RANKL bind to their receptor CSF-1R and 
RANK present in osteoclast precursor monocyte/macrophage 
cells. These ligand–receptor interactions transduce different intra-
cellular signaling cascades inside osteoclast cells, and subsequently 
promote survival, proliferation, and differentiation of osteoclast 
cells, and eventually activate osteoclast activity. Osteocytes are 
terminally differentiated osteoblast cells, and they are embedded 
into the bone matrix. Accumulating evidence documents that 
dendritic osteocytes interconnect with other bone cells through 
gap junction, and also sense the mechanical stress, minor crack, 
and changes in hormonal milieu of the bone (22, 23). Moreover, 
osteocyte cell-derived soluble factors, such as sclerostin, fibroblast 
growth factor (FGF) 23, OPG, and RANKL, regulate bone func-
tion, bone remodeling, and bone metabolism (24).
Recent studies have introduced novel molecular mechanisms 
by which osteoclast-derived factors, such as Wnt10, BMP-6, 
EphrinA2, and Semaphorin (SemaD4), regulate osteoblast 
activity (24, 25) (Figure  1). During the course of osteoclastic 
bone resorption, TGFβ and IGF-I are released in a large amount 
from the embedded bone matrix, and these growth factors may 
promote the recruitment and activation of osteoblasts in the bone 
multicellular units (26). Bone morphogenetic proteins (BMPs) 
are the most potent osteoinducers, which play a pivotal role in 
bone remodeling by regulating both osteoblast and osteoclast 
activity (27–29).
Other cell types, such as immune T cells, B cells, and stromal 
cells, also influence this bone remodeling process by supplying 
osteoclastogenic RANKL and anti-osteoclastogenic interferon 
gamma (INFγ) to the osteoclast precursor cells (Figure 1) (30, 
31). In pathophysiology condition-like arthritis, T and B cells 
both may increase osteoclastogenesis presumably by supplying 
RANKL to osteoclast cells (30–32). Various hormones, such 
as leptin, parathyroid hormone (PTH), and sex hormones, 
have been shown to regulate osteoblastic/osteoclastic function 
(23, 26, 33) (Figure 1). Thus, systemic and local environments 
manipulate the bone function, bone metabolism, and bone 
remodeling (34).
CHOLeSTeROL-LOweRiNG STATiN 
DRUGS AND HeALTH BeNeFiT
Statins are the most prescribed cholesterol-lowering drugs. 
Different members of statins, such as simvastatin, lovastatin, 
atorvastatin, pravastatin, and mevastatin, are therapeutically 
used for the treatment of CVD-like atherosclerosis. In all, statin 
treatment lowers 25–35% of serum LDL-cholesterol and reduces 
25–30% frequency of heart attack (35). Statins competitively 
inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMGCOA) reductase, a rate limiting enzyme of the cholesterol 
biosynthesis pathway in a reversible fashion (36, 37). In  vitro, 
in  vivo, and clinical studies show very promising results in 
reducing osteoporosis and cancers for statin users (10–12, 38). 
However, many studies have reported conflicting findings in 
cases of type 2 diabetes for statin users (39, 40).
CHOLeSTeROL AND OSTeOBLASTS
Research studies were carried out in cells, animal models, and 
clinical samples to evaluate the influence of serum cholesterol 
and/or cellular cholesterol on osteoblast cell proliferation, 
differentiation, and bone health. Findings of these studies are 
summarized in Table 1. In 1999, it was shown for the first time 
that the treatment of rodents with cholesterol-lowering drugs 
simvastatin and lovastatin both increased bone formation (10). 
They had found that intra-calvaria injection of these statins 
showed an increased calvarial bone formation, and similarly, 
oral administration increased cancellous bone formation (10). 
Later on, our research group had reported that treatment of 
osteoblast 2T3 cells with simvastatin and lovastatin increased 
alkaline phosphatase (ALP) activity (an early osteoblast dif-
ferentiation marker), and expression of collagen and OPN (late 
osteoblast differentiation markers) (18). As a mechanism, it 
was found that simvastatin treatment increases the expression 
of the potent osteoinducer BMP-2, by upregulating Akt and 
Erk1/2 activity to enhance osteoblast differentiation. We and 
others have reported that statins upregulate BMP-2 expression 
to increase osteoblastic ALP activity and nodule formation (10, 
18, 41, 42, 43). Similarly, simvastatin treatment was also found 
to increase cell proliferation and osteoblast differentiation of 
human periodontal ligament cells (PDLs) with concomitant 
increase of ALP, OPN, and mineralization (44). However, 
simvastatin was not found to influence proliferation/viability of 
PDLs (45). However, proliferation/viability of primary alveolar 
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osteoblast cells (AOBs) was significantly decreased by the treat-
ment of simvastatin at different concentrations (45). Simvastatin 
treatment (1 and 100 nM) was able to increase ALP activity of 
both AOBs and PDLs. Simvastatin and pravastatin treatments 
were found to increase the activity of ALP and nodule forma-
tion (46, 47). However, these treatments showed reduction of 
ALP and mineralization in aortic valve myofibroblast cells (46), 
whereas mevastatin failed to increase ALP activity and calcium 
incorporation into cells (48). Thus, the substantial data showed 
an increased osteoblastic differentiation, when osteoblast or 
osteoblast-like cells were treated with statins. But, the cell pro-
liferative response upon statin treatment depends on cell types, 
type of statins, its dosage, and duration of exposure.
In animal studies, high cholesterol diet showed a reduction 
of BMD in femur with concomitant increase of serum OCN and 
carboxyterminal collagen crosslinks (CTX), which suggests that 
high cholesterol may increase bone turn over (41). Moreover, 
treatment of osteoblast MC3T3-E cells with different concentra-
tions of cholesterol inhibited proliferation and differentiation 
(41). Cholesterol treatment reduced osteoblastic proteins Runx2, 
ALP, and collagen A1 with a concomitant decrease of BMP-2. 
These findings suggest that cholesterol may target BMP-2 to 
block the expression of Runx2, ALP, and collagen 1A in osteoblast 
cells, which in turn inhibits osteoblast differentiation. However, 
recent evidence showed that a high cholesterol diet was capable 
of masking the type 2 diabetes-induced bone loss (57). Other 
evidence documented that cholesterol-treated mesenchymal 
stem cells (MSCs) showed an increased expression of osteogenic 
lineage markers, increased ALP activity, and more mineralized 
nodule formation. It was noted that osteogenic potency of 
cholesterol was mostly due to elevation of cholesterol ester (42). 
These contrasting findings suggest that functional activity of 
cholesterol depends on disease condition, types of cholesterol 
(free cholesterol and cholesterol ester), and cell types, akin to 
statins.
Similarly, oxysterol, a cholesterol-derived product, showed 
induction of ALP, OCN, and mineralization in marrow stromal 
cells, and decreased adipocyte differentiation (50, 51). As a 
mechanism, it was found that oxysterol increased osteogenic 
markers by inhibiting DKK-1, a known Wnt inhibitor, but the 
blocking of PI3K pathway was shown to reverse the oxysterol-
induced osteogenesis in these stromal cells (58). Moreover, oxys-
terol prevented oxidized LDL-inhibited osteoblast differentiation 
of marrow stromal cells (59). However, the primary cholesterol 
metabolite, 27 hydroxycholesterol, through its actions on both 
estrogen receptors and liver X receptors, decreased osteoblast 
FiGURe 1 | A molecular view of bone remodeling with a complex interaction among bone resident cells and other cells. Here, plus and minus signs 
depict positive and negative regulator, respectively, line arrow head and blunt ended line depict increased and decreased function, respectively. Abbreviations: OC, 
osteoclast; OB, osteoblast; OBL, osteoblast lineage; MOB, mature osteoblast; OCT, osteocyte; HA, hydroxyapatite; Sema4D, semasporin 4D; CathK, cathepsin K; 
PTH, parathyroid hormone.
TABLe 1 | effect of cholesterol or cholesterol reducing drugs on osteoblast activity.
Cell types and animal 
models
Treatment Dose Duration Regulated genes Activity Reference
Osteoblast MC3T3-E1 Cholesterol 12.5–50 μg/ml 72 h Decreased BMP-2, ALP, Runx2, Collagen A1 Decreased proliferation (41)
Mouse mesenchymal  
stem cells
Cholesterol 5–15 μg/ml 48 h Increased ALP, BMP-2, Runx2, ALP, and OCN Increased cell number and nodule formation 
(after 14 days of treatment)
(42)
Vascular smooth muscle 
cells
LDLR−/− – – Decreased ALP (decreased intracellular 
cholesterol)
Decreased mineralization (49)
M2-10B4 (mouse marrow 
stromal cells)
Cholesterol-derived 
products
Oxysterol 
(20(S)-hydroxycholesterol 
22(S)-hydroxycholesterol
5 μM Exposure time 
1–8 h
Increased ALP and OCN (after 4 days) Increased Calcium incorporation (after 14 days)
Increased bone volume
(50, 51)
MCF7 breast cancer cells Osteoblast (MG63) derived 
oxysterol
Conditioned 
medium
24 h – Increased cancer cell migration (52)
Rat (ovariectomized) High cholesterol 3% Cholesterol 3 months Increased IL6 BMD less (femur) (41)
MG63 and 2T3 Simvastatin 2.5 μM 48 h BMP-2 mRNA and protein (10)
Calvaria bone (mice) Simvastatin and lovastatin 0.062–0.25 μM 72 h – Increased bone area (10)
Human periodontal 
ligament cells
Simvastatin 0.01–0.1 μM 24 h Increased ALP and osteopontin (after 7 days). 
Decreased ALP (at 10−7M)
Increased cell proliferation, increased calcium 
content (after 21 days)
(44)
Human periodontal 
ligament cells
Simvastatin 0.001–0.1 μM 24–72 h Increased ALP, OCN, OPG and RANKL Not effect on proliferation and viability (45)
Primary alveolar osteoblast 
cells
Simvastatin 0.001–0.1 μM 24–72 h Increased ALP, OCN, OPG and RANKL Decreased cell proliferation and viability (45)
Osteoblast MC3T3-E1 Simvastatin 0.1 μM 4 h (treatment) – Increased H2O2-inhibited osteoblast viability, 
decreased apoptosis, and increased osteoblast 
differentiation
(53)
Osteoblast MC3T3-E1 Simvastatin + BMP-2 0.1–1.0 μM 5 days Synergistic increased Psmad1/5 and ALP Decreased cell growth (54)
Mouse marrow stromal 
cells (M210B4)
Mevastatin 1.0–3.0 μM 2–8 days Not effect on OCN, decreased ALP Decreased calcium incorporation and cell 
number
(48)
Primary cultured marrow 
stromal cells, rat (adult)
Simvastatin 0.1–1.0 μM 10 days Increased ALP and OCN Increased mineralization (21 days), inhibited 
adipogenesis
(47)
Aortic valve  
myofibroblast cells
Simvastatin and  
pravastatin
0.1–0.6 μM – Decreased ALP Decreased mineralization (46)
M2-10B4 mouse marrow 
stromal cells
Simvastatin and  
pravastatin
0.1–0.6 μM – Increased ALP Increased mineralization (46)
2T3 osteoblast cells Lovastatin 5.0–10.0 μM Increased BMP-2, ALP, collagen, OPN – (18)
MC3T3-E1 osteoblast Simvastatin, cerivastatin, 
atorvastatin
0.1 μM 4–20 days Increased BMP-2 (6 days), ALP (12 days), type I 
collagen, BSP (20 days), and OCN (20 days)
Increased mineralization (24 days) (for all statins) (55)
Mice (ovariectomized) Simvastatin 1–10 mg/kg/day 35 days – Increased trabecular bone volume and decrease 
osteoclast number
(10)
Mice (ovariectomized) Simvastatin 10 mg/kg/day 13 weeks – No change on trabecular bone volume (56)
ALP, alkaline phosphatase; OCN, osteocalcin; OPN, osteopontin; BSP, bone sialoprotein; RANKL, receptor activator for nuclear factor kappa B ligand; OPG, osteoprotegerin; BMP-2, bone morphogenetic protein-2.
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differentiation and enhanced osteoclastogenesis, resulting in 
increased bone resorption (60).
Vascular smooth muscle cells isolated from LDL receptor 
(LDLR) knock-out mice showed reduction of ALP activity and 
matrix mineralization with a concomitant decrease of intracellu-
lar cholesterol when compared with wild type cells (49). Schilling 
et al. showed that apolipoprotein E (APOE) deficient mice showed 
an increased bone mass as compared to control mice (61).
These data indicate that different cholesterol products may 
have distinct roles in osteoblast- or osteoblast-like differentiation, 
but decreased of cellular cholesterol may prevent vascular cal-
cification, whereas increased cholesterol may inhibit osteoblast 
differentiation to prevent bone formation.
CHOLeSTeROL AND OSTeOCLASTS
Almost two decades ago, the Mundy research group suggested, 
based on rodent model experiments that statins might prevent 
osteoporosis by increasing osteoblastic differentiation and 
decreasing bone resorption (10). At that time, some clinical data 
supported the concept that cholesterol-lowering statin drugs 
might decrease the fracture risk of bone (62). Von Stechow et al. 
observations did not correlate with these findings (56). It was 
reported that treatment of macrophages with cholesterol showed 
an enhancement of osteoclast activity by increasing the expres-
sion of the interleukin alpha gene (63). Similarly, the removal of 
cellular cholesterol from osteoclast precursor cells by treating 
with cyclodextrin or high-density lipoprotein (HDL) was found 
to increase apoptosis of osteoclast cells (64). Depletion of cellular 
cholesterol has prevented RANKL- or CSF-1-driven osteoclast 
activity, presumably by inhibiting the cell survival Akt–mTOR–
S6 pathway (64). Moreover, LDLR-deficient osteoclast cells that 
might have low cellular cholesterol showed reduced size and 
life span when compared to wild type cells. Similarly, blocking 
the mevalonate pathway inhibited osteoclast activity, and also 
prevented apoptosis of osteoblast (65). More evidence showed 
that the depletion of lipid raft-cholesterol inhibits H-RAS-
induced expression of RANKL to mitigate osteoclast activity (66). 
Similarly, the integrity of lipid rafts regulate V-ATPase activity 
in osteoclast, indicating that the removal of cholesterol from 
lipid rafts may impair osteoclast function (67). All these data 
together suggest that the cellular cholesterol of osteoclast cells 
might positively influence the bone deterioration by enhancing 
osteoclast activity and preventing osteoclast apoptosis. However, 
cellular cholesterol may have a contrasting function in regulating 
apoptosis of osteoblast and osteoclast cells (64, 65).
Lovastatin treatment inhibited osteoclast differentiation by 
reducing of geranylgeranylation of prenylated proteins that inhi-
bition of geranylation and farnesylation has been shown to be 
the mechanism of action of nitrogen containing bisphosphonates, 
which are used to inhibit osteoclastic bone resorption (68, 69). 
Moreover, atorvastatin treatment to primary osteoblast cells 
showed an increased level of OPG, decoy receptor of RANKL, 
which prevents osteoblast-aided osteoclast activity by blocking 
the binding activity of RANKL to RANK receptor of osteoclast 
cells (70). It was also reported that RANKL expression of AOBs 
was increased with the treatment of simvastatin at different 
concentrations (low to high), but this expression of PDLs was 
increased only when higher concentrations of simvastatin 
(10–100 nM) were used (45). These findings indicate that statins 
may have a different cellular response in regulating RANKL 
expression. In these studies, they did not check the effect of simv-
astatin on osteoclast activity, but the expression of OPG level was 
increased in both cell types in response to simvastatin treatment 
(45). Since earlier studies documented that statin treatments 
might also increase the OPG level to block RANKL function 
(70). Thus, the RANKL/OPG ratio upon statin treatment can only 
predict the osteoclast activity.
Animal-based studies further indicate that the mice with 
hypercholesterolemia reduce the formation of cortical and 
trabecular bone in the femurs and vertebrae by promoting 
osteoclastogenesis (71). Moreover, under hypercholesterolemia 
condition, mice showed a higher risk of fracture. Similarly, high 
fat diet also induces cathepsin K positive osteoclast cells and 
RANKL expression, leading to enhanced osteoclastogenesis (72). 
Interestingly, ovariectomized (OVX) mice exhibit enhanced 
bone resorption and bone loss due to deficiency of estrogen, but 
simvastatin-treated OVX mice showed a reduction of bone 
loss by decreasing osteoclast activity (73). Similarly, in a rat 
model, a high cholesterol diet caused an enhancement of 
bone resorption with a concomitant increase of TRAP posi-
tive osteoclast cells (74).
Thus, the substantial data of cellular, animal, and clinical 
research studies suggest that the reduction of cholesterol 
might prevent bone loss by inhibiting osteoclast activity. 
Results of these studies are summarized in Table 2.
CHOLeSTeROL AND BONe MeTASTASiS
Bone is one of the most common sites for the metastasis of many 
cancer types, such as breast, prostate, ovarian, and lungs, since 
bone provides a fertile soil to disseminated tumor cells (77). During 
bone metastasis, metastasized cancer cells interrupt the normal 
bone remodeling program either by increasing osteoclast activ-
ity or by altering the osteoblast activity, as depicted in Figure 2. 
For example, breast cancers mostly show osteolytic, and prostate 
cancers often undergo osteoblastic metastasis. But in both cases, 
either abnormal osteoclast or osteoblast activity leads to increase 
the risk of bone fracture. Many growth factors and cytokines 
have been shown to participate in regulating bone metastasis. 
For example, osteoclastogenic CSF-1 plays a pivotal role in bone 
remodeling, but the abnormal expression of this cytokine cor-
relates with bone metastasis and osteoporosis (78–81).
It has been demonstrated that hyperlipidemia and high choles-
terol promote cell migration and metastasis (13, 15). The detailed 
molecular mechanism is not yet known as to how high cholesterol 
increases tumorigenesis. Although, it was hypothesized that 
statins may prevent skeletal metastasis of cancers (82). Our study, 
for the first time, experimentally documented that simvastatin 
treatment inhibits osteolytic bone metastasis, which was devel-
oped after intracardiac inoculation of human metastatic breast 
cancer MDA-MB-231 cells in mice (19).
It was suggested that simvastatin treatment increased tumor 
suppressor protein p53 levels to transcriptionally repress breast 
FiGURe 2 | A simple molecular view of osteolytic and osteoblastic metastasis of cancer. Here, plus and minus signs depict positive and negative regulator, 
respectively, line arrow head and blunt ended line depict increased and decreased function, respectively. Abbreviations: OC, osteoclast; OB, osteoblast;  
OBL, osteoblast lineage; CC, cancer cells; CathK, cathepsin K.
TABLe 2 | effect of cholesterol or cholesterol reducing drugs on osteoclast function.
Types of cells, animal model, 
clinical data
Treatment for alteration 
cholesterol level
Regulated genes Activity Reference
Macrophages Cholesterol Increased IL6 Increased osteoclast activity (63)
Osteoclast cells Removal of cholesterol  
(by cyclodextrin or HDL)
Inhibited RANKL/CSF-1-induced 
osteoclast activity
(64)
Murine preosteoblast (CIMC4) Removal of cholesterol  
(by cyclodextrin)
Inhibited RANKL – (66)
Bone marrow-derived osteoclast Removal of cholesterol  
(by cyclodextrin)
Inhibited V-ATPase Inhibited osteoclast activity (67)
Human primary osteoblast cells Atorvastatin Increased OPG Inhibited osteoclast activity (70)
Breast cancer and multiple  
myeloma
Simvastatin Inhibited RANKL l-induced NFκB pathway Inhibited RANKL-induced osteoclast (75)
Ovariectomized rat Simvastatin Decreased Trap Decreased osteoclast (73)
Rat High cholesterol Increased Trap Increased osteoclast (74)
Mice High cholesterol Increased osteoclast (71)
Rabbit High fat diet Increased RANKL, MCP-1, Cathepsin K Increased osteoclast (72)
Multiple myeloma patients Simvastatin Increased Trap (serum) Bone resorption (76)
RANKL, receptor activator for nuclear factor kappa B ligand; OPG, osteoprotegerin; CSF-1, colony stimulating factor-1; Trap, tartrate resistant acid phosphatase; MCP-1, monocyte 
chemoattractant protein-1.
October 2015 | Volume 6 | Article 1656
Mandal Cholesterol and bone
Frontiers in Endocrinology | www.frontiersin.org
FiGURe 3 | A proposed molecular mechanism by which simvastatin 
inhibits bone metastasis of cancer. Line arrow head and blunt ended line 
depict increased and decreased function, respectively, and up and bottom 
arrow show increased and decreased level/expression, respectively.
October 2015 | Volume 6 | Article 1657
Mandal Cholesterol and bone
Frontiers in Endocrinology | www.frontiersin.org
cancer stem cell marker CD44 expression. This in turn inhibits 
the breast cancer cell migration and invasion, resulting in the 
inhibition of osteolytic metastasis (19). Later on, another research 
group had demonstrated that simvastatin treatment prevents 
osteolytic lesions of the spinal cord, which was produced due to 
injection of the lung cancer A549 into nude mice. Similar to our 
observation, they had also suggested that simvastatin treatment 
upregulated p53 protein with concomitant increase of CD44, 
MMP-2, and MMP-9 (83). Our research study also proved that 
metastatic breast cancer cells secrete more CSF-1 as compared 
to non-metastatic breast cancer cells (84). Other study reported 
that statins inhibit CSF-1 expression (85). These data suggest that 
breast cancer cell-derived CSF-1 might potentiate osteolytic bone 
loss, which could be inhibited by the treatment of statins. Recently, 
a study has shown that the combination of simvastatin and the 
anti-diabetic drug metformin synergistically reduced the meta-
static property of cancer cells as well as metastasis to the spinal 
cord and femurs. In this study, prostate cancer C4-2B cells were 
injected into castrated aythmic mice to develop metastasis (86). 
The combination of these two drugs inhibited AKT and AMPKα 
activity (86). We had reported earlier that simvastatin treatment 
upregulated the tumor suppressor protein PTEN. PTEN inhibits 
AKT activity in preventing cancer growth both in in vitro and an 
animal model (87). These findings indicate that cholesterol may 
positively modulate bone metastasis of cancers. Clinical evidence 
supports this concept, since the mean cholesterol level was found 
to be increased in bone metastases when compared to healthy 
controls (88).
Altogether, these data support the idea that cellular cholesterol 
might potentiate bone metastasis of cancers. Based on these 
findings, a potential molecular mechanism by which statins 
inhibit cholesterol-mediated bone metastasis has been proposed 
(Figure 3).
CHOLeSTeROL AND MULTiPLe 
MYeLOMA
Clinical findings suggest that serum cholesterol level of 
myeloma patients is low, since myeloma cancer cells consume 
more serum cholesterol for their growth (89). Exogenous treat-
ment of cholesterol increases cell survival of myeloma cells (90). 
Myeloma cancer cells may increase cellular cholesterol either 
by inhibiting cholesterol efflux or increasing sterol regulatory 
element binding (SERB) transcription factors, which transcrip-
tionally increase HMGCOA reductase and LDLR expression 
(91). More evidence showed that simvastatin treatment was 
quite capable to inhibit myeloma driven osteoclast activity, 
which was promoted by RANKL treatment (75). In contrast to 
the above studies, Sondergaard et al. reported that a high dose 
of simvastatin treatment to multiple myeloma patients showed 
elevated levels of TRAP and CTX in serum, indicating that 
simvastatin treatment might increase bone resorption, instead 
of inhibition (76).
These conflicting results indicate that cholesterol-lowering 
drugs may prevent myeloma-induced bone diseases, provided 
the drugs reduce the cellular cholesterol of the myeloma cells.
CONCLUSiON
Low BMD and the occurrence of bone fractures are strong predictors 
for osteoporosis. Many research studies have strengthened the link 
between the serum lipid profile and BMD. Here, the relationship 
between cholesterol and BMD has been summarized in Table 3. 
Substantial data showed a negative association between BMD and 
serum TC, and LDL cholesterol (5, 7, 8, 92–97). A few studies found 
no association and/or a positive association with serum cholesterol 
and LDL cholesterol (98–101). The summarized data from all the 
studies indicate that there is an existence of an inconsistent relation-
ship for the case of HDL cholesterol and BMD (6, 99, 100, 102). 
In several clinical trials, but not in all, the use of statins have been 
associated with a reduction of fracture risk, and the patients taking 
statins having a higher BMD than those who do not (103–105). In 
brief, a high cholesterol level is inversely associated with BMD, and 
statin treatment shows an enhancement of BMD, indicating high 
cholesterol as a negative regulator of bone health.
However, the existence of this inverse relationship was not 
always found (Table 3). Thus, it could be that serum cholesterol 
or cholesterol-lowering drugs might have a variable influence in 
regulating BMD at different sites. The effect of serum cholesterol 
on BMD may vary among individuals, by gender, with age, and 
menopausal status of women. However, if we summarize all results 
of cell culture and animal experiments (Tables 1 and 2), it can be 
TABLe 3 | Relationship between cholesterol and BMD.
Lipid types Relationship between BMD and cholesterol Subjects Reference
LDL cholesterol Inverse association with BMD at 1/3 radial, distal radial, and lumbar Postmenopausal women (92)
Cholesterol Inverse association with BMD at lumbar spine and distal forearm  
but not with hip
Postmenopausal women (94)
Cholesterol and LDL cholesterol Inverse association with BMD at spine and hip Postmenopausal women (93)
Cholesterol and LDL cholesterol Inverse association with BMD at spine, hip, and forearm Postmenopausal women (96)
Cholesterol and LDL cholesterol Inverse association with BMD at lumbar and femoral neck Early postmenopausal women (95)
Cholesterol and LDL-cholesterol Inverse association with BMD at trochanter, shaft and proximal total hip Pre and postmenopausal women (97)
Cholesterol and LDL-cholesterol Inverse association with BMD at lumbar and whole body Postmenopausal women (5)
Cholesterol Inverse association with BMD Premenopausal women (8)
Cholesterol/HDL cholesterol and 
LDL cholesterol/HDL cholesterol
Inverse association with BMD Men with dyslipidemia (7)
Cholesterol and LDL cholesterol No association with BMD at lumbar spine and femur neck Postmenopausal women (99)
Cholesterol and LDL-cholesterol No association with BMD at femoral neck, trochanter, intertrochanteric 
zone, and lumbar vertebrae
Male (100)
Cholesterol and LDL cholesterol No association with BMD Premenopausal women (101)
Cholesterol Positive association with BMD at total body and at all sites but  
not with neck
Postmenopausal women (98)
HDL cholesterol Positive association with BMD at 1/3 radial, distal radial, and lumbar Postmenopausal women (92)
HDL cholesterol Positive association with BMD at trochanter Postmenopausal women (6)
HDL cholesterol Positive association with BMD at femur neck Postmenopausal women (99)
HDL cholesterol Positive association with BMD at femur neck Male (100)
HDL cholesterol Inverse association with BMD at femur neck and total hip Premenopausal women (101)
HDL cholesterol Inverse association with BMD at femur neck Pre and postmenopausal women (102)
LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMD, bone mineral density.
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